Cinpanemab
- Generic Name
- Cinpanemab
- Drug Type
- Biotech
- CAS Number
- 2094516-02-4
- Unique Ingredient Identifier
- W83JGQ40XX
- Background
Cinpanemab is under investigation in clinical trial NCT03318523 (Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease).
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Japanese Participants With Parkinson's Disease
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2021-05-25
- Lead Sponsor
- Biogen
- Target Recruit Count
- 24
- Registration Number
- NCT03716570
- Locations
- 🇯🇵
Research Site, Kodaira-shi, Tokyo-To, Japan
Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Participants With Parkinson's Disease
- First Posted Date
- 2017-10-24
- Last Posted Date
- 2022-02-28
- Lead Sponsor
- Biogen
- Target Recruit Count
- 357
- Registration Number
- NCT03318523
- Locations
- 🇬🇧
Royal Hallamshire Hospital, Sheffield, West Midlands, United Kingdom
🇺🇸University of Kansas Medical Center Research Institute, Kansas City, Kansas, United States
🇺🇸Cedars Sinai, Los Angeles, California, United States
Single-Ascending Dose Study of BIIB054 in Healthy Participants and Early Parkinson's Disease
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Biogen
- Target Recruit Count
- 66
- Registration Number
- NCT02459886
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath